{
    "name": "gadoxetate",
    "comment": "Rx",
    "other_names": [
        "Eovist",
        "Gadoxetic Acid"
    ],
    "classes": [
        "Gadolinium-Containing Contrast Agents",
        "Contrast Media",
        "Ionic/Low Osmolality"
    ],
    "source": "https://reference.medscape.com/drug/eovist-gadoxetic-acid-gadoxetate-343774",
    "pregnancy": {
        "common": [
            "GBCAs cross the placenta and result in fetal exposure and gadolinium retention",
            "Human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive",
            "Estimated background risk of major birth defects and miscarriage for the indicated population is unknown",
            "All pregnancies have a background risk of birth defect, loss, or other adverse outcomes"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Estimated infant exposure is 0.001%-0.04% of the maternal dose",
            "Unknown whether the effects of the drug on the breastfed infant or the effects of the drug on milk production",
            "Developmental and health benefits of breastfeeding should be considered together with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Nephrogenic systemic fibrosis",
                    "description": [
                        "Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs",
                        "Avoid use of GBCAs in these patients unless diagnostic information is essential and not available with noncontrasted MRI or other modalities",
                        "NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs",
                        "Highest risk for NSF is among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73²) OR acute kidney injury",
                        "Screen patients for acute kidney injury and other conditions that may reduce renal function",
                        "For patients at risk for chronically reduced renal function (eg, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing",
                        "For patients at highest risk for NSF, do not exceed recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity; history of allergy/drug reactions"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Caution in thrombotic syndromes; anemia, hepatic impairment; hemoglobinopathies (sickle cell anemia); history of grand mal seizure",
                "In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis reported with the use of some gadolinium-based contrast agents; risk of acute kidney injury might be lower with gadoxetate due to its dual excretory pathways; do not exceed recommended dose",
                "Risk for nephrogenic systemic fibrosis (NSF) in patients w/ acute or chronic severe renal insufficiency, hepatorenal syndrome or in perioperative liver transplantation period",
                "Screen patients for kidney disease before use and monitor renal function afterward; nephrogenic systemic fibrosis (NSF) associated with use of gadolinium contrast media in patients with kidney disease; do not exceed recommended dose",
                "Risk of hypotension",
                "Tissue damage/reactions reported with extravasation"
            ],
            "specific": [
                {
                    "type": "Gadolinium retention",
                    "description": [
                        "Gadolinium is retained for months or years in several organs",
                        "Highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (eg, brain, skin, kidney, liver, and spleen)",
                        "Duration of retention also varies by tissue and is longest in bone",
                        "Patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions are at higher risk of gadolinium retention",
                        "Brain deposits",
                        "FDA investigated the risk of brain deposits following repeated use of GBCAs for MRI in 2015",
                        "Publications in the medical literature have reported that deposits of GBCAs remain in the brains of some patients who undergo ≥4 contrast MRI scans, long after the last administration",
                        "As of 2017, the FDA review had not identified adverse health effects from gadolinium retained in the brain after the use of GBCAs MRI; all GBCAs may be associated with some gadolinium retention in the brain and other body tissues",
                        "Early data in rat studies show that linear GBCAs are more prone to dissociation into free gadolinium and demonstrate greater brain deposition than macrocyclic GBCAs, which are less prone to dissociation"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Dizziness",
            "percent": "1"
        },
        {
            "name": "Flushing sensation",
            "percent": "1"
        },
        {
            "name": "Headache",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": "1"
        },
        {
            "name": "Back pain",
            "percent": "1"
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Akathisia",
            "percent": null
        },
        {
            "name": "Altered sense of smell",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Hyperhidrosis",
            "percent": null
        },
        {
            "name": "Increased blood pressure",
            "percent": null
        },
        {
            "name": "Increased serum bilirubin",
            "percent": null
        },
        {
            "name": "Maculopapular rash",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Nephrogenic systemic fibrosis",
            "percent": null
        },
        {
            "name": "Oral discomfort",
            "percent": null
        },
        {
            "name": "Palpitations",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Respiratory distress",
            "percent": null
        },
        {
            "name": "Restlessness",
            "percent": null
        },
        {
            "name": "Sialorrhea",
            "percent": null
        },
        {
            "name": "Skin rash",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Xerostomia",
            "percent": null
        }
    ]
}